The dollar stayed near a 2-1/2-year low on Wednesday as investors assessed the likelihood of further fiscal stimulus in the United States, while riskier currencies held onto gains as investor confidence improved. The Chinese yuan erased some gains in Asian afternoon trade after the New York Times reported that U.S. President-elect Joe Biden will not immediately act to remove the Phase 1 trade agreement President Donald Trump signed with China. The Euro and the Kiwi steadied after an overnight jump to their 2 1/2-year highs as dollar weakened broadly on renewed hopes for a coronavirus vaccine and U.S. fiscal stimulus.
A promise of dialogue between the Cuban government and artists calling for greater freedom of expression seems to have stalled, after communist authorities blamed a protest on US interference.
College basketball fans are getting a first glimpse at how loaded this freshman class is with future NBA draft picks. Here's an early assessment of the players and teams that are impressing early this season.
On a recent sunny morning in New York a few dozen people gathered in Central Park's wooded Ramble area with a common goal: zero in on an elusive owl.
Cricket Australia and the A-League are the big winners of the NSW Government's eased COVID-19 restrictions, with major stadiums now back to full capacity.
Basel, 2 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto™ (pralsetinib) for the treatment of adult and paediatric patients 12 years of age and older with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) who require systemic therapy, or with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). These indications were approved under the FDA’s accelerated approval programme based on data from the phase I/II ARROW study. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. “We are proud to partner with Blueprint Medicines to bring this important new option to people with certain types of RET-altered thyroid cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Gavreto is now approved across multiple RET-altered tumour types, underscoring our commitment to advancing personalised healthcare with treatments that target the underlying biology of each person’s cancer.”Approximately 10-20% of people with papillary thyroid cancer (the most common type of thyroid cancer)1 have RET fusion-positive tumours,2 and roughly 90% of people with advanced MTC (a rare form of thyroid cancer) carry RET mutations.3 Biomarker testing for RET fusions and mutations can help identify people who are eligible for treatment with Gavreto.The approvals are based on results from the phase I/II ARROW study, which demonstrated durable clinical activity in people with or without prior therapy and regardless of RET alteration genotypes.4 Treatment with Gavreto led to an overall response rate (ORR) of 60% (95% CI: 46%, 73%) in 55 people with RET-mutant metastatic MTC previously treated with cabozantinib and/or vandetanib, and the median duration of response (DoR) was not reached (95% CI: 15.1 months, not estimable).2 In 29 people with cabozantinib- and vandetanib-naïve RET-mutant advanced MTC who were determined to be not eligible for standard therapies, the ORR was 66% (95% CI: 46%, 82%), and the median DoR was not reached (95% CI: not estimable, not estimable).4 In nine people with RET fusion-positive metastatic thyroid cancer, Gavreto demonstrated an ORR of 89% (95% CI: 52%, 100%), and the median DoR was not reached (95% CI: not estimable, not estimable).4 In ARROW trial patients across RET-altered tumour types, the most common adverse reactions (≥25%) were constipation, increased blood pressure (hypertension), fatigue, musculoskeletal pain and diarrhoea.4The FDA reviewed and approved the application under its Real-Time Oncology Review (RTOR) pilot programme, which aims to explore a more efficient review process to ensure safe and effective treatments are available to patients as early as possible. In September, the FDA also granted accelerated approval to Gavreto for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. In addition, the FDA granted Breakthrough Therapy Designation to Gavreto for the treatment of RET mutation-positive MTC that requires systemic treatment and for which there are no acceptable alternative treatments and for RET fusion-positive NSCLC that has progressed following platinum-based chemotherapy.Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations. About the ARROW study5 ARROW (NCT03037385) is a phase I/II, open-label, first-in-human study designed to evaluate the safety, tolerability and efficacy of Gavreto, administered orally in people with rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC), RET fusion-positive thyroid cancer and other RET-altered solid tumours. The trial consists of two parts: a dose escalation portion, which is complete, and an expansion portion in people treated with 400 mg of Gavreto, once-daily. ARROW is being conducted at multiple sites across the United States, European Union and Asia. About RET-altered cancers RET gene alterations, such as fusions and mutations, are key disease drivers in many types of cancer, including NSCLC and several types of thyroid cancers. Approximately 10-20% of people with papillary thyroid cancer (the most common type of thyroid cancer)1 have RET fusion-positive tumours,2 and roughly 90% of people with advanced MTC (a rare form of thyroid cancer) carry RET mutations.3 In NSCLC, RET fusions represent approximately 1-2% of patients.6 Oncogenic RET fusions also are observed at low frequencies in cholangiocarcinoma, colorectal, neuroendocrine, ovarian, pancreatic and thymus cancers. About Gavreto Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations, regardless of the tissue of origin. Preclinical data have shown that Gavreto inhibits primary RET fusions and mutations that cause cancer in subsets of patients, as well as secondary RET mutations predicted to drive resistance to treatment. Blueprint Medicines and Roche are co-developing Gavreto for the treatment of patients with various types of RET-altered cancers.Blueprint Medicines and Roche are co-developing Gavreto globally, excluding Greater China.* Blueprint Medicines and Genentech, a wholly owned member of the Roche Group, will co-commercialise Gavreto in the US and Roche has exclusive commercialisation rights for Gavreto outside of the US, excluding Greater China.*About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. * Greater China encompasses Mainland China, Hong Kong, Macau and TaiwanAll trademarks used or mentioned in this release are protected by law. References  Cancer Treatment Centers of America. Thyroid Cancer Types [Internet; cited 2020 October]. Available from: https://www.cancercenter.com/cancer-types/thyroid-cancer/types  Santoro M et al. RET Gene Fusions in Malignancies of the Thyroid and Other Tissues. Genes 2020;11(4):424  Li A et al. RET fusions in solid tumours. Cancer Treat Rev. 2019;81:101911  Blueprint Medicines. Data on file.  ClinicalTrials.gov. Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) [Internet; cited 2020 October]. Available from: https://clinicaltrials.gov/ct2/show/NCT03037385  Drilon et al. Targeting RET-Driven Cancers: Lessons From Evolving Preclinical And Clinical Landscapes. Nat Rev Clin Oncol. 2018;15:151‒67. Roche Group Media Relations Phone: +41 61 688 8888 / e-mail: firstname.lastname@example.org Dr. Nicolas Dunant Phone: +41 61 687 05 17 Patrick Barth Phone: +41 61 688 44 86 Dr. Daniel Grotzky Phone: +41 61 688 31 10 Karsten Kleine Phone: +41 61 682 28 31 Nina Mählitz Phone: +41 79 327 54 74 Nathalie Meetz Phone: +41 61 687 43 05 Dr. Barbara von Schnurbein Phone: +41 61 687 89 67 Roche Investor Relations Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: email@example.com Jon Kaspar Bayard Phone: +41 61 68-83894 e-mail: firstname.lastname@example.org Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: email@example.com Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: firstname.lastname@example.org Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: email@example.comDr. Gerard Tobin Phone: +41 61 68-72942 e-mail: firstname.lastname@example.org Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: email@example.comDr. Lisa Tuomi Phone: +1 650 467 8737 e-mail: firstname.lastname@example.org Attachment * 02122020_MR_FDA approval of Gavreto_en
The Morrison government will work with states to look at safety reforms to protect delivery drivers after the deaths of five people on Sydney roads.
England may be finishing its second national lockdown, but for many familieslike mine, the first lockdown never really ended.
Europe Inactive Dry Yeast Industry for Animal Feed Application is set to register over 5.5% CAGR between 2020 and 2026, owing to growing meat consumption driven by need to enhance the protein intake.Selbyville, Delaware, Dec. 02, 2020 (GLOBE NEWSWIRE) -- The Europe inactive dry yeast market for animal feed application is expected to reach over USD 80 Million by 2026, according to a new research report by Global Market Insights, Inc. Rising demand for animal nutrition products in order to maintain their health and enhance their growth will foster the market expansion. Embargo on antibiotic growth promoters by EU commission in manufacturing animal foods has resulted in increasing R&D activities in Yeast Products for rumen microbial populations, gastrointestinal ecosystem, and animal performance. These factors will drive the growth of Europe inactive dry yeast industry for animal feed application.Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/4871The majority of the bovine population is kept in France, Germany, Ireland, Italy, and Spain. Spain and Germany have the maximum pig population in the region. In 2018, the European Union produced approximately 7.9 million tonnes of bovine meat, which signifies a growth of over 1.5% compared to the previous year. The animals are also used to produce milk. Such factors will lead to an increased product demand in the region to maintain the proper growth of the livestock. Some major findings of the Europe inactive dry yeast market for animal feed application report include: * Prevalence of animal diseases such swine flu has shifted the focus towards improving the immunity system of animals is augmenting the industry growth. * Increasing meat consumption driven by need to enhance the protein intake is likely to fuel the business expansion. * Some of the key manufacturers in the market include Leiber Germany, Alltech Belgium/ Ireland, ADM, Sensient and Angel Yeast. * Europe inactive dry yeast market from poultry application witnessed highest growth potential and is further anticipated to grow due to Increase in per-capita meat consumption along with rise in livestock production. * UK holds a substantial share in the market and is further forecasted to grow owing to rising poultry industry.Browse key industry insights spread across 230 pages with 219 market data tables and 30 figures & charts from the report, “Europe Inactive Dry Yeast Market for Animal Feed Application By Application (Poultry [Broiler, Layer, Turkey], Swine [Starter, Grower, Sow], Cattle [Dairy, Calf], Aquaculture [Salmon, Trout’s, Shrimps, Carp], Pet Food, Equine), Country Outlook, Industry Analysis Report, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 – 2026” in detail along with the table of contents:https://www.gminsights.com/industry-analysis/europe-inactive-dry-yeast-market-for-animal-feed-applicationEurope Inactive Dry Yeast Market for animal feed application from petfood is expected to register over 3% CAGR through 2026. Pet food segment garnered revenue of USD 10.46 Million in 2019. Inactive dry yeasts serve as an essential ingredient for pet food owing to its nutritional and protein content. It helps in maintaining and building muscles, bones, blood and improving digestion. Increasing prevalence of pet adoption, rising disposable income, and changing perceptions toward diet are likely to boost the product demand in Europe. Pet owners are shifting from traditional food items cooked at home to high-quality packaged pet food which will drive the industry statistics. Increasing demand for high nutritional pet food triggered by rapid pace of social and economic changes, humanization of pet, and growing concerns pertaining to obesity in pets will create significant growth opportunity in the European market.Europe Inactive Dry Yeast Market for animal feed application from France exceeded USD 7.5 Million in 2019 and is expected to witness over 5.5% CAGR through 2026. Increased meat consumption in France and growing demand for meat exports from over the world, have led to increased consumption of feed additives and supporting the France market demand. Industrialization of meat production, increasing demand for nutritional and protein rich products is fuelling the product demand in France. Europe Inactive Dry Yeast Industry for animal feed application from Equine is expected to achieve over 3% CAGR through 2026. Equine belongs to the mammal family of Equidae that includes modern horses, zebras, and donkeys. Inactive dry yeast is used as feed additive to increase endurance and reduce their fatigue. Additionally, growing horse ownership and increasing individual interest in horses in Europe is one of the key reasons fuelling the market growth of equine feed. Thus, the growing number of house ownership and increasing awareness about their food the nutritional benefits offered by these products should support the European market landscape.Access the Toc of this report @ https://www.gminsights.com/toc/detail/europe-inactive-dry-yeast-market-for-animal-feed-applicationBrowse Related Report:Yeast Market For Animal Feed Application By Application (Poultry [Broiler, Layer, Turkey], Swine [Starter, Grower, Sow], Cattle [Dairy, Calf], Aquaculture [Salmon, Trouts, Shrimps, Carp], Pet Food, Equine), Products (Autolyzed Yeast, Hydrolyzed Yeast, Dried Inactive Yeast, Yeast Culture, Live Yeast, Yeast Beta-Glucan, Active Dry Yeast), Industry Analysis Report, Regional Outlook, Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2020 – 2026https://www.gminsights.com/industry-analysis/yeast-market-for-animal-feed-applicationAbout Global Market InsightsGlobal Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology. CONTACT: Contact Us: Arun Hegde Corporate Sales, USA Global Market Insights, Inc. Phone: 1-302-846-7766 Toll Free: 1-888-689-0688 Email: email@example.com
The Extraordinary General Meeting of Nordic Fibreboard AS (registry code: 11421437, address: Suur-Jõe 48, Pärnu 80042, hereinafter the Company) will be held on the 23th of December 2020 at 9.am at the Uus street 1, Pärnu, Anne Kaldvee notary office.The Management Board asks the shareholders to consider that due to the COVID-19 disease caused by the coronavirus it is advisable to minimize the extent of and participation in physical gatherings. Therefore, the Management Board urges the shareholders to vote on the draft resolutions prepared in respect to the items on the agenda of the general meeting using electronic means prior to the general meeting, and not to participate the general meeting in person.In order to vote using electronic means the shareholders have to fill in a voting ballot – the ballot is attached to the notice on convening the general meeting both on the website of Nasdaq Baltic stock exchange (https://nasdaqbaltic.com/) as well as of Nordic Fibreboard https://group.nordicfibreboard.com/en/investor/extraordinary-general-meeting , and forward it by e-mail to firstname.lastname@example.org no later than 16.00 on 22 December 2020 either 1. signed digitally or 2. scanned with a hand-written signature and with a copy of the personal information page of the identical document.A more detailed procedure for electronic voting is attached to the notice convening the general meeting on the above-mentioned websites.The agenda of the General Meeting with the proposals of the Supervisory Board: 1. Changes in the Supervisory BoardProposal of the Supervisory Board: to recall Jan Peter Ingman from the position of Supervisory Board member.Documents related to the Extraordinary General Meeting, including draft resolutions, are available at Rääma 31 Pärnu and on the Company's website https://group.nordicfibreboard.com/en/investor/extraordinary-general-meetingAs of the date of publishing of the announcement, the share capital of Nordic Fibreboard AS is 269 943,66 euros. The company has 4,499,061 no par value shares and each share gives one vote.The date of closing the list of shareholders entitled to vote at the Extraordinary General Meeting will be December 16, 2020 at end of trading day.Registration of the participants in the meeting will begin at 8:45.To register yourself as a participant in the general meeting, please present: * a shareholder who is a sole proprietor – an identity document * a representative of a shareholder who is a sole proprietor – an identity document and a written authorization document * a representative of a shareholder who is a legal person – valid certified copy of the registry card (for legal persons in Estonia, certified no earlier than 7 days ago), which entitles the person to represent the shareholder, and an identity document of the representative, or an authorization document prepared as required and an identity document of the representative. We request prior legalization or apostille certification of documents of a legal person registered in a foreign country, unless stated otherwise in the international agreement. Nordic Fibreboard AS may register a shareholder who is a legal person of a foreign country as a participant in the general meeting also in case all required data on the legal person and the representative are included in the notarized authorization document issued to the representative in a foreign country and the authorization document is acceptable in Estonia. If a shareholder has deposited his/her shares on a nominee account, a respective certificate issued by the account administrator shall be submitted, certifying the right of ownership of the shares as of December 16, 2020. * Please present your passport or identity card as an identification document.A shareholder may notify the Company of the appointment of a representative or withdrawal of authorization by a representative by submitting respective information to the Management Board of Nordic Fibreboard AS (in a digitally signed format which can be reproduced in writing on the following e-mail address: email@example.com, or in writing by mail at the following address: Nordic Fibreboard AS, Suur-Jõe 48, Pärnu, Estonia) no later than on 22th of December 2020 (inclusive).For the appointment of a representative or withdrawal of authorization by a representative, a shareholder may use the forms available on the website of Nordic Fibreboard AS https://group.nordicfibreboard.com/en/investor/extraordinary-general-meetingTorfinn LosvikCEO & Chairman of the Management Board Phone: + 372 56 99 09 88 E-mail: firstname.lastname@example.orgAttachments * Voting ballot_23 12 2020 Nordic Fibreboard * Power of Attorney Nordic Fibreboard - 23 12 2020 * Withdrawal of POA_Nordic Fibreboard AS- 23 12 2020 * Draft resolutions_ Additional information for the Extraordinary General Meeting of Shareholders * PROCEDURE OF THE ELECTRONIC VOTING OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF NORDIC FIBREBOARD AS * Information to shareholders about participation at the Extraordinary General Meeting 23 12 .2020
Gyroscope Therapeutics Announces Appointments of Industry Veterans in Gene Therapy, Ophthalmology and Biopharmaceuticals to its Board of Directors.
* Elecsys® Anti-SARS-CoV-2 S test specifically detects antibodies against the SARS-CoV-2 spike protein * The spike protein is the target of many COVID-19 vaccines in development * This test may help identify recovering patients who could potentially be serum and plasma donors for developing treatments for COVID-19 Basel, 2 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its Elecsys® Anti-SARS-CoV-2 S antibody test has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). The serology (blood) test can be used to measure the level of antibodies in people who have been exposed to the SARS-CoV-2 virus. The EUA in the United States follows the launch of the Elecsys® Anti-SARS-CoV-2 S antibody test for markets accepting the CE Mark announced on 18 September.The new test targets antibodies that are directed against the region of the novel coronavirus known as the spike protein, specifically the area that enables the virus to bind to a host cell receptor, which is required for the virus to enter the host cell.1,2 Many current candidate vaccines aim to induce an antibody response against the SARS-CoV-2 spike protein. Tests that quantify antibodies to the spike protein could be used to measure the level of that response and track that measurement over time. The test provides a numerical result describing the concentration of antibodies from 0.40-250 U/mL as well as a qualitative result.“Since the start of this pandemic, our focus has been to bring effective diagnostic testing solutions to the fight against COVID-19,” said Thomas Schinecker, CEO of Roche Diagnostics. “Antibody tests like these will play a critical role in measuring a person’s vaccine-induced immune response”. In addition to its role in helping to measure a patient’s immune response, the test may help guide the allocation of plasma donations from recovered COVID-19 patients to current patients by identifying donors that have antibodies to SARS-CoV-2 virus. Convalescent plasma therapy is an investigational procedure that separates and removes the plasma from a patient’s blood. This plasma is then replaced with plasma from a donor to give the ill patient antibodies to help fight the virus. The laboratory-based Elecsys Anti-SARS-CoV-2 S test runs on Roche’s widely available cobas e analyzers and is the latest addition to Roche’s growing diagnostic portfolio to help healthcare systems combat COVID-19 through testing in the laboratory and at the point of care. Currently, this portfolio includes molecular, serology and digital solutions that help healthcare professionals diagnose COVID-19 and provide optimal patient care during the initial stages of infection and the recovery phase, as well as following the resolution of infection.About SARS-CoV-2 Coronaviruses (CoV) are a large family of viruses that cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). The novel coronavirus (SARS-CoV-2) is a new strain which has not previously been identified in humans.Signs of infection include respiratory symptoms such as cough, shortness of breath, difficulty breathing and fever. In more severe cases, pneumonia, severe acute respiratory syndrome, kidney failure and death can occur.3About the Elecsys® Anti-SARS-CoV-2 S test The Elecsys® Anti-SARS-CoV-2 S test is an immunoassay for the in vitro determination of antibodies to SARS-CoV-2. Through a blood sample, the test can measure antibodies to the spike protein of the coronavirus, which could signal whether a person has been already infected. The test has both a high negative percent agreement (NPA) of 99.98% (N=5991) and positive percent agreement (PPA) of 96.6% (N=233), 15 days or later after diagnosis with a PCR test. With this test, Roche also showed titer development over time for patient samples ranging >100 days following a reactive PCR result, with no samples showing a decline of titers below the reactive range. Additionally, across panels of potentially cross-reactive samples (N=1100) from endemic human coronaviruses, infectious respiratory diseases, other infectious diseases, auto-immune and liver related diseases, the test demonstrated zero cross-reactivity. This test has been authorized only for the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens.Clinical laboratories can run these tests on Roche’s cobas e analyzers which are widely available around the world. These fully automated systems can provide antibody test results in approximately 18 minutes, with a test throughput of up to 300 tests/hour, depending on the analyzer.4About Roche’s response to the COVID-19 pandemic To address the global COVID-19 healthcare crisis, Roche has developed a growing number of diagnostic solutions that help detect and diagnose the infection in patients, as well as providing digital support to healthcare systems. Roche also continues to identify, develop and support potential therapies that can play a role in treating the disease.Reliable, high-quality testing is essential to help healthcare systems overcome this pandemic. Roche continues to work with healthcare providers, laboratories, authorities and organizations to help make sure that patients continue to receive the tests, treatment and care they need during these challenging times. The Roche portfolio of COVID-19 solutions includes: * a high-volume molecular test to detect SARS-CoV-2, the virus that causes COVID-19, (FDA Emergency Use Authorization (EUA) and available in countries accepting the CE Mark) * a SARS-CoV-2 laboratory-based antibody test, aimed at detecting the presence of antibodies in the blood targeting the nucleocapsid (FDA EUA and CE Mark) * an IL-6 test to assist in identifying severe inflammatory response in patients with confirmed COVID-19 (FDA EUA and CE Mark) * a high-volume molecular test to simultaneously detect and differentiate between SARS-CoV-2 and influenza A/B, as the symptoms are similar for both (FDA EUA and CE Mark) * a second SARS-CoV-2 antibody test, aimed at measuring antibody response to the spike protein, to help assess a patient’s immune response and support the development of convalescent plasma therapy * a point-of-care molecular PCR test that simultaneously detects and differentiates between SARS-CoV-2 and influenza A/B infections to support urgent triage and diagnosis (FDA EUA and CE Mark) About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References  Masters PS (2006). The molecular biology of coronaviruses. Advances in Virus Research. Academic Press. 66: 193–292  Hoffmann, Markus et al. (2020). Cell. 81(2):271-280.e8  https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html  Full specifications of the Roche immunoassay systems, including throughput, can be found on our diagnostics.roche.com website Roche Group Media Relations Phone: +41 61 688 8888 / e-mail: email@example.com Dr. Nicolas Dunant Phone: +41 61 687 05 17 Patrick Barth Phone: +41 61 688 44 86 Dr. Daniel Grotzky Phone: +41 61 688 31 10 Karsten Kleine Phone: +41 61 682 28 31 Nina Mählitz Phone: +41 79 327 54 74 Nathalie Meetz Phone: +41 61 687 43 05 Dr. Barbara von Schnurbein Phone: +41 61 687 89 67 Roche Investor Relations Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: firstname.lastname@example.org Jon Kaspar Bayard Phone: +41 61 68-83894 e-mail: email@example.com Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: firstname.lastname@example.org Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: email@example.com Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: firstname.lastname@example.orgDr. Gerard Tobin Phone: +41 61 68-72942 e-mail: email@example.com Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: firstname.lastname@example.orgDr. Lisa Tuomi Phone: +1 650 467 8737 e-mail: email@example.com Attachment * 02122020_MR_FDA EUA Elecsys Anti-SARS-CoV-2 S test_en
In Germany's industrial heartland, engineering firms have come up with a recipe for surviving the coronavirus pandemic. Keep spending on research and development even if sales drop, build a financial buffer so you can craft a long-term business plan, be flexible with dealers to keep supply chains intact, have an innovative mindset and see crises as opportunities. It's certainly a strategy that is paying off for some of the small and mid-sized "Mittelstand" companies (SMEs) that together provide almost 60% of all jobs in Germany, according to Reuters interviews with six chief executives.
Vopak and BlackRock's GEPIF successfully completed the acquisition of three industrial terminals from Dow on the U.S. Gulf CoastRotterdam, the Netherlands, 2 December 2020 Royal Vopak and BlackRock's Global Energy & Power Infrastructure Fund (GEPIF) successfully completed the earlier announced acquisition of three industrial terminals from Dow (NYSE: DOW) on the U.S. Gulf Coast. This acquisition was announced on 14 September 2020. Dow had selected the new 50/50 joint venture of Royal Vopak and BlackRock's GEPIF to acquire three major industrial terminals on the U.S. Gulf Coast for the amount of USD 620 million. The name of the new joint venture is Vopak Industrial Infrastructure Americas, LLC, which has a diversified set of infrastructure assets, in three locations, with each situated alongside an active Dow production complex. Vopak Industrial Infrastructure Americas has entered into long-term service agreements with Dow, for storage and infrastructure services. Dow expects Vopak's terminal expertise and capabilities will deliver additional operational efficiencies and opportunities for growth. The total capacity of the three terminals is 852,000 cubic meters (cbm). The Freeport, Texas, terminal has 53 tanks (140,000 cbm) for storage of chemicals. The St. Charles, Louisiana, terminal has 73 total tanks (409,000 cbm) for storage of chemicals. The Plaquemine, Louisiana, terminal has 30 tanks (303,000 cbm) for storage of chemicals and refined products. The involved assets include 16.4 hectares of expansion land, 36 vessel berths, multiple pipeline connections, rail and truck racks. About Vopak Royal Vopak is the world’s leading independent tank storage company. We store vital products with care. With over 400 years of history and a focus on sustainability, we ensure safe, clean and efficient storage and handling of bulk liquid products and gases for our customers. By doing so, we enable the delivery of products that are vital to our economy and daily lives, ranging from chemicals, oils, gases and LNG to biofuels and vegoils. We are determined to develop key infrastructure solutions for the world’s changing energy systems, while simultaneously investing in digitalization and innovation. Vopak is listed on the Euronext Amsterdam and is headquartered in Rotterdam, the Netherlands. For more information, please visit www.vopak.com. About BlackRock BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, our clients turn to us for the solutions they need when planning for their most important goals. As of September 30, 2020, the firm managed approximately $7.81 trillion in assets on behalf of investors worldwide. For additional information on BlackRock, please visit www.blackrock.com | Twitter: @blackrock | www.linkedin.com/company/blackrock. For further information please contact: Vopak Press Liesbeth Lans, Manager External Communication, Telephone : +31 (0)10 4002777, e-mail: firstname.lastname@example.org Vopak analysts and investors Laurens de Graaf, Head of Investor Relations Telephone : +31 (0)10 4002776, e-mail: email@example.com BlackRock Curtis Chou, Corporate Communications Telephone: +1 646-231-1031, e-mail: firstname.lastname@example.org Attachment * Download full press release
Online simulation provider SimScale and Zaha Hadid Architects announce a free webinar with a focus on early-stage design simulation on the cloud.
Taiwan External Trade Development Council (TAITRA), the operator of the nation’s largest B2B portal Taiwantrade.com, has launched the 2020 Medical Online Show.
Marseille, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2021 financial calendar: March 18, 2021: Publication of 2020 financial statementsMay 11, 2021: Publication of revenue for 1Q2021May 28, 2021: Annual General Shareholders MeetingSeptember 15, 2021: Publication of half year financial statementsNovember 16, 2021: Publication of revenue for 3Q2021All financial reports are released before market open CET.All corporate information, such as the Company’s financial statements and corporate presentations, is available on https://investors.innate-pharma.com. About Innate Pharma:Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.Learn more about Innate Pharma at www.innate-pharma.com Information about Innate Pharma shares:ISIN code Ticker code LEIFR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 Disclaimer on forward-looking information and risk factors:This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.For additional information, please contact:Investors Innate Pharma Tel.: +33 (0)4 30 30 30 30 email@example.com Media Innate Pharma Tracy Rossin (Global/US) Tel.: +1 240 801 0076 Tracy.Rossin@innate-pharma.com ATCG Press Marie Puvieux (France) Tel.: +33 (0)9 81 87 46 72 firstname.lastname@example.org Attachment * Financial Calendar 2021 Press Release
The dollar stayed near a 2-1/2-year low on Wednesday as investors assessed the likelihood of further fiscal stimulus in the United States, while riskier currencies held onto gains as investor confidence improved. Against a basket of major currencies, the dollar index eased at 91.19, near the lowest level since late April 2018 it hit overnight. The Euro and the Kiwi steadied after an overnight jump to their 2 1/2-year highs as dollar weakened broadly on renewed hopes for a coronavirus vaccine and U.S. fiscal stimulus.
The cold temperatures of last weekend's Fuji SUPER GT season finale was the main reason for a "disaster" race for Nissan's flagship NISMO GT-R, says Ronnie Quintarelli.
Senior Rebels bikie member Sami Esko Hamalainen has walked out of the NSW Supreme Court a free man following his involvement with the murder of another member.